Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Derived Cells for Chronic Limb Ischemia at High Risk of Amputation
2025-520937-22-00Phase 2Authorised
- Sponsor
- FINBA
- Start
- Feb 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2 trial of autologous bone marrow-derived cells in chronic limb-threatening ischaemia (CLTI) (2 arms), sponsored by FINBA. Primary endpoint: Anatomic and functional changes induced by somatic cell therapy. Planned start Feb 2025; status: authorised.
02
Drugs
autologous bone marrow-derived cells
03
Conditions
chronic limb-threatening ischaemia (CLTI)
Beyond the preview
Go deeper on 2025-520937-22-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520937-22-00.